Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/52016
Campo DC Valoridioma
dc.contributor.authorWägner, A. M.en_US
dc.contributor.authorCloos, P.en_US
dc.contributor.authorBergholdt, R.en_US
dc.contributor.authorBoissy, P.en_US
dc.contributor.authorAndersen, T. L.en_US
dc.contributor.authorHenriksen, D. B.en_US
dc.contributor.authorChristiansen, C.en_US
dc.contributor.authorChristgau, S.en_US
dc.contributor.authorPociot, F.en_US
dc.contributor.authorNerup, J.en_US
dc.date.accessioned2018-11-25T16:44:18Z-
dc.date.available2018-11-25T16:44:18Z-
dc.date.issued2007en_US
dc.identifier.issn0012-186Xen_US
dc.identifier.urihttp://hdl.handle.net/10553/52016-
dc.description.abstractAims/hypothesis Post-translational modifications, such as isomerisation of native proteins, may create new antigenic epitopes and play a role in the development of the autoimmune response. Protein-L-isoaspartate (D-aspartate) O-methyltransferase (PIMT), encoded by the gene PCMT1, is an enzyme that recognises and repairs isomerised Asn and Asp residues in proteins. The aim of this study was to assess the role of PIMT in the development of type 1 diabetes. Materials and methods Immunohistochemical analysis of 59 normal human tissues was performed with a monoclonal PIMT antibody. CGP3466B, which induces expression of Pcmt1, was tested on MIN6 and INS1 cells, to assess its effect on Pcmt1 mRNA and PIMT levels (RT-PCR and western blot) and apoptosis. Forty-five diabetes-prone BioBreeding (BB) Ottawa Karlsburg (OK) rats were randomised to receive 0, 14 or 500 μg/kg (denoted as the control, low-dose and high-dose group, respectively) of CGP3466B from week 5 to week 20. Results A high level of PIMT protein was detected in beta cells. CGP3466B induced a two- to threefold increase in Pcmt1 mRNA levels and reduced apoptosis by 10% in MIN6 cells. No significant effect was seen on cytokine-induced apoptosis or PIMT protein levels in INS1 cells. The onset of diabetes in the BB/OK rats was significantly delayed (85.6 ± 9.0 vs 84.3 ± 6.8 vs 106.6 ± 13.5 days, respectively; p < 0.01 for high-dose vs low-dose and control groups), the severity of the disease was reduced (glucose 22.2 ± 3.2 vs 16.9 ± 2.6 vs 15.8 ± 2.7 mmol; p < 0.01 for high- and low-dose groups vs control group) and residual beta cells were more frequently identified (43% vs 71% vs 86%; p < 0.05 for high-dose vs control group) in the treated animals. Conclusions/interpretation The results support a role for post-translational modifications and PIMT in the development of type 1 diabetes in the diabetes-prone BB rat, and perhaps also in humans.en_US
dc.languageengen_US
dc.relation.ispartofDiabetologia (Berlin)en_US
dc.sourceDiabetologia[ISSN 0012-186X],v. 50, p. 676-681 (Enero 2007)en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject.otherBB raten_US
dc.subject.otherINS1 cellsen_US
dc.subject.otherMIN6 cellsen_US
dc.subject.otherPreventionen_US
dc.titlePost-translational protein modifications in type 1 diabetes: A role for the repair enzyme protein-l-isoaspartate (D-aspartate) O-methyltransferase?en_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s00125-006-0556-1en_US
dc.identifier.scopus33846826589-
dc.contributor.authorscopusid7401456520-
dc.contributor.authorscopusid6701430960-
dc.contributor.authorscopusid6603090798-
dc.contributor.authorscopusid55376159900-
dc.contributor.authorscopusid9745064100-
dc.contributor.authorscopusid6701438851-
dc.contributor.authorscopusid36040368300-
dc.contributor.authorscopusid7003540725-
dc.contributor.authorscopusid7005502287-
dc.contributor.authorscopusid7103405350-
dc.description.lastpage681en_US
dc.description.firstpage676en_US
dc.relation.volume50en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages6en_US
dc.utils.revisionen_US
dc.date.coverdateEnero 2007en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.jcr5,822-
dc.description.jcrqQ1-
dc.description.scieSCIE-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-7663-9308-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameWägner, Anna Maria Claudia-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

16
actualizado el 17-nov-2024

Citas de WEB OF SCIENCETM
Citations

13
actualizado el 17-nov-2024

Visitas

45
actualizado el 03-mar-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.